Montreal, Quebec
Calcitonin in Osteogenesis Imperfecta SIR,-Your recent leading article (17 February, p. 371) refers to a preliminary investigation on the effect of calcitonin in osteogenesis imperfecta. Several workers have used calcitonin in this disorderl 2 and have suggested' that it may have a therapeutic place. We think that this suggestion is premature. Ignorance of the cause of a disorder need not necessarily prevent attempts at treatment. Thus in Paget's disease, where the cause remains completely obscure, there is overwhelming biochemical and histological evidence of increased and disorderly bone formation and resorption, which is presumably the direct cause of the changes in the bones and the complications which follow. Attempts to suppress this increased bone turnover therefore seem logical, and in Paget's disease the well-documented ability of calcitonin to reduce bone resorption is therapeutically useful.
In osteogenesis imperfecta the situation is different. Some measurements of bone histology3 and urinary total hydroxyproline excretion4 suggest excess bone resorption, although these findings are not unanimously aocepted. Even if resorption is increased it is by no means clear that it is an important part of the disease process and should therefore be suppressed, rather than a physiological response to other primary changes in the bone. In either case calcitonin will reduce total hvdroxyproline excretion, but there is no evidence that this effect is desirable therapeutically.
There is no consensus of opinion about the cause of osteogenesis imperfecta. Recent work on abnormal pyrophosphate5 and leucocyte metabolism has not been confirmed,67 and there is no convincing evidence of a primary defect in mineralization. On clinical and pathological grounds it has been thought for manv years that the inherited features of the disease are due to an abnormalitv of co]laven. Knowledge of collac'en biochemistry is now sufficiently advanced8 for such a suraestion to be d;rectly investigated in tissues or in fibroblasts grown from them. Preliminary data suggest an abnormality of collaLyen cross-linking in at least some patients with osteorenesis imperfecta9 and agree with the clinical observations that it is not a homogeneous disorder. Recent work, which shows that the types of cross-link in fetal collaten differ from those of later life,'0 and that there are chemical differences between the collagen of cartilaee and bone," provides for the possibility of many collaeen defecs which could resemble each other clinically.
Osteogenesis imperfecta is a significant cause of severe crimnling, and any advance in treatment is to be welcomed. At present, however, there seems to be insufficient evidence to suggest that calcitonin is a rational treatnent for this disorder. Dr. Wallis assumes that imipramine always preceded the monoamine oxidase inhibitor. This was not so. Orders of ad-ministration of antidepressants were randomized, as were orders of intravenous infusions (as mentioned in the paper), and subjects did not know when doses and drugs were changed. We regret that failure to report the order of experiments led Dr. Wallis to an erroneous supposition.
Further, a rise in blood pressure precipitated by anxiety would ordinarily be accompanied by a rise in heart rate. We found, however, that the pressor response during phenylephrine and noradrenaline infusions was always accompanied by marked bradycardia. The control infusions gave reproducible responses in this series of experiments as in the many previous series we have conducted.
Our results accord with those of others in both man' and animals.2 There is now substantial evidence that sympathomimetic amines can produce serious cardiovascular effects in patients being treated with tricyclic antidepressant agents. Previous premature birth produced very similar effects:
